Inductive Bio won an award — up to $21 million — from ARPA‑H to lead an industrial‑academic consortium developing next‑generation AI models for drug toxicity prediction, focusing initially on drug‑induced liver injury and cardiotoxicity. Partners include Amgen, Cincinnati Children’s, Baylor, Torch Bio and others; the project will generate data from advanced human model systems (organoids, ex vivo tissues, microphysiological systems) to train AI models for regulatory use. Separately, Ginkgo Bioworks and Deep Origin joined a $31.7 million ARPA‑H consortium to advance in‑silico and ex‑vivo safety models. These programs aim to reduce reliance on animal testing, improve early detection of human safety liabilities and decrease late‑stage clinical attrition. Sources: ARPA‑H award announcements and consortium press materials.